GlassScriptPhysician profile
Karissa Thal
NPI 1033679691
$72,274.00
in general payments reported to CMS, 2019-2025
24 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.44 · 2021: $42.39 · 2022: $383 · 2023: $1,646 · 2024: $18K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $15K · Food and Beverage: $6,128 · Travel and Lodging: $4,743 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,906.80 |
| Consulting Fee | $15,032.50 |
| Food and Beverage | $6,128.23 |
| Travel and Lodging | $4,743.13 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36,248.41 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $33,425.24 | 2023-2025 | |
| Novo Nordisk INC | $590.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $550.36 | 2022-2025 | Mounjaro, Emgality, Zepbound |
| Glaxosmithkline, LLC. | $457.35 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Lundbeck LLC | $306.42 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $153.03 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $74.85 | 2023-2024 | Evenity, Aimovig |
| Impel Pharmaceuticals INC. | $64.46 | 2023 | Trudhesa |
| Dexcom, INC. | $63.15 | 2023-2025 | Dexcom G6 Transmitter |
| Tonix Medicines, INC. | $53.64 | 2025 | Zembrace Symtouch |
| Exact Sciences Corporation | $38.31 | 2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $34.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $31.61 | 2022-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $29.23 | 2023-2025 | Eliquis, Camzyos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.44 | 2023 | Enspryng, Ocrevus |
| Merck Sharp & Dohme LLC | $21.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.22 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $16.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.86 | 2023 | Combivent Respimat, Spiriva Respimat, Stiolto Respimat |
| Amneal Pharmaceuticals LLC | $15.65 | 2023 | Rytary |
| Upsher-Smith Laboratories LLC | $14.42 | 2022 | |
| Abbott Laboratories | $14.28 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $13.60 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karissa Thal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.